Utah Medical Products Inc
UTMD Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$74.23
KIRA · Stoqly’s AI analyst, in plain words
- Utah Medical Products Inc had $38.5M of revenue in fiscal 2025, down 5.8% on the year before. Over five years, revenue changed −1.8% a year on average.
- Its operating margin was 29.6%, down 3.6 pts: of every 100 in sales, about 30 is left after running the business.
- Utah Medical Products Inc made $11.3M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 0.9% a year.
- Free cash flow was $14.3M in fiscal 2025, 37.2% of revenue.
- Utah Medical Products Inc returned $12.3M to shareholders in fiscal 2025, 86% of free cash flow. The diluted share count fell 7.5%.
- Utah Medical Products Inc has $85.8M more cash than debt.
Market cap
$236M
P/E
22.6x
Revenue
$38.5M
Net income
$11.3M
Free cash flow
$14.3M
Operating margin
29.6%
Utah Medical Products Inc in 30 seconds · fiscal 2025
Are sales growing?
−5.8%
No. Sales fell 5.8% last year.
Does it make a profit?
29.3%
Yes. It keeps 29.3% of every sale as profit.
Does profit turn into cash?
37.2%
Yes. 37.2% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
22.6x
One share costs 22.6 times its yearly profit per share.
What Utah Medical Products Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 27, 2026
- Legal name
- UTAH MEDICAL PRODUCTS INC
- CIK
- 0000706698
Utah Medical Products Inc · UTMD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $49.1M | $52.3M | $50.2M | $40.9M | $38.5M |
| Revenue growth | 16.3% | 6.6% | −3.9% | −18.6% | −5.8% |
| Gross margin | 63.0% | 61.6% | 59.8% | 59.0% | 57.1% |
| Operating margin | 38.5% | 37.9% | 33.4% | 33.2% | 29.6% |
| Net income | $14.8M | $16.5M | $16.6M | $13.9M | $11.3M |
| Net margin | 30.1% | 31.5% | 33.1% | 33.9% | 29.3% |
| Diluted EPS | $4.04 | $4.52 | $4.57 | $3.96 | $3.48 |
| Cash | |||||
| Cash from operations | $21.2M | $21.1M | $22.3M | $14.8M | $14.7M |
| Capital expenditure | $0.6M | $0.8M | $0.6M | $0.2M | $0.4M |
| Free cash flow | $20.7M | $20.3M | $21.6M | $14.6M | $14.3M |
| FCF margin | 42.1% | 38.9% | 43.1% | 35.7% | 37.2% |
| Dividends paid | $11.5M | $3.2M | $4.3M | $4.3M | $4.0M |
| Share buybacks | $0.0M | $2.5M | $0.0M | $20.0M | $8.4M |
| Share count change | −0.3% | −0.5% | −0.2% | −3.7% | −7.5% |
| Debt and strength | |||||
| Cash and short-term investments | $61.0M | $75.1M | $92.9M | $83.0M | $85.8M |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $107M | $114M | $128M | $117M | $119M |
| Net debt / EBITDA | −3.1x | −3.7x | −5.3x | −5.8x | −7.0x |
| Current ratio | 19.5x | 15.1x | 22.6x | 25.6x | 37.6x |
| Returns and quality | |||||
| Return on capital | 31.7% | 40.3% | 39.2% | 32.6% | 27.2% |
| Return on equity | 14.1% | 14.9% | 13.7% | 11.3% | 9.5% |
| Return on tangible equity | 19.6% | 18.2% | 15.2% | 13.7% | 10.8% |
| Piotroski F-score | 8 | 5 | 5 | 5 | 5 |
| Altman Z'' | 21.5 | 21.3 | 27.9 | 33.3 | 47.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Utah Medical Products Inc · UTMD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $74.23 a share, the company is worth $236M: 22.6 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0000706698). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.